+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group



Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group



Aids 10(13): 1521-1527



To study the predictive value of anti-Toxoplasma gondii antibody titres for the occurrence of toxoplasmic encephalitis (TE) in HIV-infected patients. Data from the placebo arm of a trial of primary prophylaxis for TE (ANRS 005/ACTG 154) were analysed. Patients included had CD4+ cell counts < 200 x 10(6)/l and a positive Toxoplasma serology. Immunoglobulin (Ig) G and IgM Toxoplasma antibody titres at entry were retrospectively determined by enzyme-linked immunosorbent assay and agglutination on serum samples in a single laboratory. Incidence of TE was estimated by Kaplan-Meier method and a Cox model was used to study the predictive value of antibody titres, adjusted for other covariates. All 164 patients studied were positive for IgG antibodies and one had IgM antibodies. After a mean follow-up of 16 months, 31 cases of TE were documented. One-year incidence of TE was significantly higher in patients with IgG titres > or = 150 IU/ml (23.7%) than in patients with titres < 150 IU/ml (7.7%; relative risk, 3.1; P < 0.003). IgG titres remained significantly associated with the occurrence of TE (relative risk, 3.3; P < 0.005) in the Cox model. Predictive value of IgG titres did not differ according to baseline CD4+ cell counts. In patients with CD4+ cell counts < 200 x 10(6)/l, IgG anti-Toxoplasma antibody titre is a prognostic factor of occurrence of TE, with a higher risk for titres > or = 150 IU/ml. This finding should reinforce the recommendation of specific prophylaxis in these patients.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047040218

Download citation: RISBibTeXText

PMID: 8931787


Related references

Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. AIDS (London) 10(13): 1521-1527, 1996

Importance of Toxoplasma gondii antibody titres in patients with toxoplasmic encephalitis and AIDS. Journal of Neurovirology 8(Supplement 1): 91, 2002

Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clinical Infectious Diseases 34(9): 1243-1250, 2002

Induction of toxoplasmic encephalitis by injection of a monoclonal antibody to interferon gamma in mice chronically infected with various strains of toxoplasma gondii. Journal of Leukocyte Biology (SUPPL 2): 68-69, 1991

Predictive value of toxoplasma gondii IgG antibody titer on the occurrence of cerebral toxoplasmosis in HIV-infected patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 35(0): 211, 1995

Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. New England Journal of Medicine 329(14): 995-1000, 1993

Primary prophylaxis of toxoplasmosis encephalitis in HIV-infected patients Use of co-trimoxazole in the long-term follow-up of ANRS 005/ACTG 154 trial. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 37: 269, 1997

Survival after AIDS-defining events in patients with < 200 lymphocytes CD4+ x 10(6)/L who are toxoplasmosis antibody positive. ANRS 005/ACTG 154 Trial Group. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 14(5): 459-464, 1997

Effect of the strain of Toxoplasma gondii on the development of toxoplasmic encephalitis in mice treated with antibody to interferon-gamma. Parasitology Research 80(2): 125-130, 1994

A multicentre prospective study for the polymerase chain reaction detection of Toxoplasma gondii DNA in blood samples from 186 AIDS patients with suspected toxoplasmic encephalitis. Bio-Toxo Study Group. Aids 11(15): 1888-1890, 1997

Intrathecal production of antibodies against toxoplasma gondii in patients with toxoplasmic encephalitis and aids. Clinical Research 35(1): 191A, 1987

Role of Toxoplasma gondii HSP70 and Toxoplasma gondii HSP30/bag1 in antibody formation and prophylactic immunity in mice experimentally infected with Toxoplasma gondii. Microbiology and Immunology 43(5): 471-479, 1999

High predictive value of Toxoplasma gondii IgG antibody levels in HIV-infected patients for diagnosis of cerebral toxoplasmosis. European Journal of Clinical Microbiology and Infectious Diseases 15(11): 869-872, 1996

High risk of developing toxoplasmic encephalitis in AIDS patients seropositive to Toxoplasma gondii. Medical Microbiology and Immunology 180(2): 59-66, 1991

In vitro anti-Toxoplasma gondii antibody production by peripheral blood mononuclear cells in the diagnosis and the monitoring of toxoplasmic encephalitis in AIDS-related brain lesions. Journal of Acquired Immune Deficiency Syndromes 25(3): 256-260, 2000